Skip to main content
Equibles
CMMB logo

CMMB · Chemomab Therapeutics Ltd.

Track CMMB — free

Use CMMB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CMMB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.48 -0.13 (-4.98%) At close · Sep 21
Rebalance outlook locked
Market Cap
$18.69M
Shares
7.33M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.48 Open$2.65 Day$2.46–2.70 52W close$1.36–3.50 Avg vol 30d101K Short int103K · 1.4% float · 1.0d Short vol53% Last earningsMay 11, 2023 DataJan 2020–Sep 2026 Filing10-Q · May 11

Up next

Latest filing: 10-Q
filed May 11, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-137.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.1%
Year over year · more shares
Price change (1Y)
-6.4%
Trailing year
Short interest
1.4%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +34%
above
Price vs 50-day avg +20%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 52%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +15%
trailing
6-month return +68%
trailing
YTD return +50%
this year
Relative strength +45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-13% holders QoQ · +1 funds added
Insider flow Distributing
Net -$6.5K over 90 days · 100% sells
Short interest Falling
1.40% of float · ▼ -9.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Poor
EPS growth −54%
Y/Y
Free cash flow $-11.1M
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −61%
past year
ATR 8.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+34% Bullish
Price vs 50-day avg
+20% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
52% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-13% holders QoQ · +1 funds added
Insider flow Distributing
Net -$6.5K over 90 days · 100% sells
Short interest Falling
1.40% of float · ▼ -9.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 52% Range high $4
vs 200-day avg +34% vs 50-day avg +20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CMMB
Chemomab Therapeutics Ltd.
this stock
$18.69M +50.3% — — 1.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.84B +12.7% +46.2% 29.6 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.80B +3.4% +20.8% 19.4 2.5%
MRNA
Moderna, Inc.
 $61.50B +486.4% +4.3% — 9.8%
ARGX
Argenx SE
 $60.93B +17.5% — — 2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
13
% held
5.2%
Net QoQ
+28.3K sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
102.7K
Days to cover
1.0d
Change
-10.5K sh
View
Short Volume
Short vol %
53%
As of
Sep 21, 2026
Short Total
View
Fails to Deliver
FTD shares
14.5K
Value
$39.6K
As of
Aug 28, 2026
View
Off-Exchange
Off-exchange %
55.5%
Week of
Aug 17, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$6.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-9.0M
EPS diluted
$0.02
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 19, 2026
This year
9
View
Proposed Sales
Value
$1.0M
Shares
500.0K
Filed
Sep 12, 2024
View
Exempt Offerings
Offering
$10.0M
Filed
Aug 9, 2024
View
Earnings & Events
Earnings Calls
Last call
Sep 11, 2026
View

Performance

5D 20D 120D MTD YTD
CMMB +1.2% +14.8% +67.6% -8.8% +50.3%
SPY +1.7% +1.0% +22.4% +0.8% +13.4%
vs SPY -0.4% +13.8% +45.2% -9.7% +36.9%
Key facts CIK 1534248 CUSIP 16385C203 13F (30d) 1 filings 1 filers Visit website Investor relations